Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 have demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy. 

AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care lipid-lowering therapies such as statins. 

The new data were presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo in Chicago, Illinois, US and published in JACC.  

At 12 weeks, AZD0780 30mg taken once-daily (when added to the standard-of-care statin therapy and administered without any fasting or food restrictions) led to a 50.7% reduction in LDL-C.  

Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin doses at baseline. 

In addition, AZD0780 30mg enabled 84% of trial participants to meet their American Heart Association/American College of Cardiology guideline-recommended LDL-C target (<70mg/dL), compared to 13% of participants on background statin therapy alone.  

Dr Michael Koren, CEO & Medical Director of Jacksonville Center for Clinical Research, Florida, US and PURSUIT Principal Investigator, said: “The PURSUIT Phase IIb trial demonstrates the potential of AZD0780 to provide a much-needed once-daily oral treatment option to deliver greater LDL cholesterol lowering on top of standard of care for millions of patients who remain at risk for serious cardiovascular events including premature death. These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors.”  

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, added: “As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater convenience for patients.” 

Diana Spencer, Senior Digital Content Editor, DDW